Danaher Co. (NYSE:DHR) Shares Bought by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC grew its stake in Danaher Co. (NYSE:DHRFree Report) by 472.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,670 shares of the conglomerate’s stock after purchasing an additional 7,982 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Danaher were worth $2,237,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Banco Santander S.A. acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $683,000. Parkside Financial Bank & Trust increased its position in shares of Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the period. Keybank National Association OH lifted its holdings in Danaher by 0.5% in the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after acquiring an additional 2,567 shares during the last quarter. Kingsview Wealth Management LLC grew its position in Danaher by 1.0% in the third quarter. Kingsview Wealth Management LLC now owns 17,346 shares of the conglomerate’s stock worth $4,303,000 after buying an additional 172 shares during the last quarter. Finally, Lcnb Corp raised its position in shares of Danaher by 21.9% during the second quarter. Lcnb Corp now owns 2,229 shares of the conglomerate’s stock worth $535,000 after purchasing an additional 400 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now owns 14,129 shares in the company, valued at $3,548,498.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 over the last 90 days. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several recent research reports. Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. TheStreet raised Danaher from a “c+” rating to a “b-” rating in a research note on Friday, December 8th. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Barclays lowered Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 target price on the stock. in a report on Wednesday, January 24th. Finally, KeyCorp upped their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $266.00.

View Our Latest Report on DHR

Danaher Trading Down 2.7 %

Shares of Danaher stock opened at $247.94 on Tuesday. The business’s 50 day moving average is $245.80 and its 200-day moving average is $230.45. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The stock has a market cap of $183.40 billion, a P/E ratio of 38.80, a P/E/G ratio of 3.87 and a beta of 0.84. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHRGet Free Report) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the previous year, the business posted $2.87 earnings per share. Danaher’s quarterly revenue was down 10.2% on a year-over-year basis. Equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be given a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 15.02%.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.